European competition authorities have traditionally been wary of pursuing cases of “excessive” or “unfair” medicine prices, not least because the burden of proof is high and it is generally accepted that action should be started only in exceptional cases. Change is in the air, though, and the number of investigations undertaken has risen noticeably in recent years.
Decisions over the next year or two in recent cases brought forward by competition authorities are expected to help clarify...